Giuseppe
Emeritus
[Source: The Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]
Highly pathogenic avian influenza H5N1 mutants with air-transmissibility are susceptible to human and animal neutralizing antibodies
Lanying Du 1, Ye Li 1, Guangyu Zhao 2, Lili Wang 1, Peng Zou 1, Lu Lu 3, Yusen Zhou 2 and Shibo Jiang 1,3
Author Affiliations: <SUP>1</SUP>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA <SUP>2</SUP>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China <SUP>3</SUP>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China
Reprints or correspondence: Dr. Yusen Zhou, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China (yszhou@bmi.ac.cn); or, Dr. Shibo Jiang, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA (sjiang@nybloodcenter.org).
Abstract
A laboratory-generated reassortant H5 hemagglutinin (HA)/H1N1 virus containing four mutations in H5N1 HA become airborne transmissible among mammals. Here we constructed 15 H5N1 pseudoviruses containing single and combinations of these mutations, and showed that these H5N1 pseudoviruses were sensitive to neutralizing antibodies from H5N1-infected patients and conserved H5N1 HA1 sequence-immunized mice. These results indicate that antibodies in patients currently infected by H5N1 and those induced by vaccines containing conserved sequences in HA1 of wild-type H5N1 are highly effective in cross-neutralizing future H5N1 mutants with airborne transmissibility, suggesting that human flu pandemics potentially caused by these H5N1 variants can be preventable.
Received February 26, 2013. Revision received March 24, 2013. Accepted March 27, 2013.
? The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com.
-
------
Highly pathogenic avian influenza H5N1 mutants with air-transmissibility are susceptible to human and animal neutralizing antibodies
Lanying Du 1, Ye Li 1, Guangyu Zhao 2, Lili Wang 1, Peng Zou 1, Lu Lu 3, Yusen Zhou 2 and Shibo Jiang 1,3
Author Affiliations: <SUP>1</SUP>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA <SUP>2</SUP>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China <SUP>3</SUP>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China
Reprints or correspondence: Dr. Yusen Zhou, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China (yszhou@bmi.ac.cn); or, Dr. Shibo Jiang, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA (sjiang@nybloodcenter.org).
Abstract
A laboratory-generated reassortant H5 hemagglutinin (HA)/H1N1 virus containing four mutations in H5N1 HA become airborne transmissible among mammals. Here we constructed 15 H5N1 pseudoviruses containing single and combinations of these mutations, and showed that these H5N1 pseudoviruses were sensitive to neutralizing antibodies from H5N1-infected patients and conserved H5N1 HA1 sequence-immunized mice. These results indicate that antibodies in patients currently infected by H5N1 and those induced by vaccines containing conserved sequences in HA1 of wild-type H5N1 are highly effective in cross-neutralizing future H5N1 mutants with airborne transmissibility, suggesting that human flu pandemics potentially caused by these H5N1 variants can be preventable.
Received February 26, 2013. Revision received March 24, 2013. Accepted March 27, 2013.
? The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com.
-
------